Drug-drug interaction between itraconazole and the antiretroviral drug lopinavir/ritonavir in an HIV-1-infected patient with disseminated histoplasmosis.

Kristel M L Crommentuyn; Jan W. Mulder; Rolf W. Sparidans; Alwin D R Huitema; Jan H M Schellens; Jos H. Beijnen

Drug-drug interaction between itraconazole and the antiretroviral drug lopinavir/ritonavir in an HIV-1-infected patient with disseminated histoplasmosis.

Kristel M L Crommentuyn^*
, Jan W. Mulder
, Rolf W. Sparidans
, Alwin D R Huitema
, Jan H M Schellens
, Jos H. Beijnen

^*Corresponding author for this work

Pharmacoepidemiology and Clinical Pharmacology

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

We describe a drug-drug interaction between coformulated lopinavir/ritonavir and itraconazole in a patient infected with human immunodeficiency virus type 1 who had disseminated histoplasmosis. Coadministration of these agents led to a strong increase in itraconazole concentrations and a decrease in concentrations of its metabolite, hydroxyitraconazole, which is equally active pharmacologically. The dosage of itraconazole was reduced when it was used in combination with lopinavir/ritonavir.

Original language	English
Pages (from-to)	e73-5
Number of pages	3
Journal	Clinical Infectious Diseases
Volume	38
Issue number	8
Publication status	Published - 2004

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Cite this

@article{63f5733a1bd74f4cae717fe5c0d50154,

title = "Drug-drug interaction between itraconazole and the antiretroviral drug lopinavir/ritonavir in an HIV-1-infected patient with disseminated histoplasmosis.",

abstract = "We describe a drug-drug interaction between coformulated lopinavir/ritonavir and itraconazole in a patient infected with human immunodeficiency virus type 1 who had disseminated histoplasmosis. Coadministration of these agents led to a strong increase in itraconazole concentrations and a decrease in concentrations of its metabolite, hydroxyitraconazole, which is equally active pharmacologically. The dosage of itraconazole was reduced when it was used in combination with lopinavir/ritonavir.",

author = "Crommentuyn, \{Kristel M L\} and Mulder, \{Jan W.\} and Sparidans, \{Rolf W.\} and Huitema, \{Alwin D R\} and Schellens, \{Jan H M\} and Beijnen, \{Jos H.\}",

year = "2004",

language = "English",

volume = "38",

pages = "e73--5",

journal = "Clinical Infectious Diseases",

issn = "1058-4838",

publisher = "Oxford University Press",

number = "8",

}

Drug-drug interaction between itraconazole and the antiretroviral drug lopinavir/ritonavir in an HIV-1-infected patient with disseminated histoplasmosis. / Crommentuyn, Kristel M L; Mulder, Jan W.; Sparidans, Rolf W. et al.
In: Clinical Infectious Diseases, Vol. 38, No. 8, 2004, p. e73-5.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Drug-drug interaction between itraconazole and the antiretroviral drug lopinavir/ritonavir in an HIV-1-infected patient with disseminated histoplasmosis.

AU - Crommentuyn, Kristel M L

AU - Mulder, Jan W.

AU - Sparidans, Rolf W.

AU - Huitema, Alwin D R

AU - Schellens, Jan H M

AU - Beijnen, Jos H.

PY - 2004

Y1 - 2004

N2 - We describe a drug-drug interaction between coformulated lopinavir/ritonavir and itraconazole in a patient infected with human immunodeficiency virus type 1 who had disseminated histoplasmosis. Coadministration of these agents led to a strong increase in itraconazole concentrations and a decrease in concentrations of its metabolite, hydroxyitraconazole, which is equally active pharmacologically. The dosage of itraconazole was reduced when it was used in combination with lopinavir/ritonavir.

AB - We describe a drug-drug interaction between coformulated lopinavir/ritonavir and itraconazole in a patient infected with human immunodeficiency virus type 1 who had disseminated histoplasmosis. Coadministration of these agents led to a strong increase in itraconazole concentrations and a decrease in concentrations of its metabolite, hydroxyitraconazole, which is equally active pharmacologically. The dosage of itraconazole was reduced when it was used in combination with lopinavir/ritonavir.

UR - https://www.scopus.com/pages/publications/2342650264

M3 - Article

C2 - 15095234

AN - SCOPUS:2342650264

SN - 1058-4838

VL - 38

SP - e73-5

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

IS - 8

ER -

Drug-drug interaction between itraconazole and the antiretroviral drug lopinavir/ritonavir in an HIV-1-infected patient with disseminated histoplasmosis.

Abstract

UN SDGs

Other files and links

Fingerprint

Cite this